PHARMACOECONOMIC ASPECTS OF USE OF INHALED AND INTRAVENOUS ANESTHETICS
The results of the analysis of Russian and foreign studies on pharmacoeconomic aspects of the use of inhaled and intravenous anesthetics (for example, halothane, sevoflurane and propofol) and treatments for complications caused by those are presented. It was found that formally the costs associated with the use of sevoflurane are higher than those of halothane, but actually the costs for treatments for complications caused by halothane anesthesia are lower and the quality of anesthesia administration and the degree of safety of sevoflurane anesthesia are greater. Halothane can cause severe liver damage in 25% of cases, which in 50% of cases leads to a fatality and requires the only possible treatment option - liver transplantation. Also, inhalation anesthesia with sevoflurane reduces costs by 2,0-3,5 times compared to generic propofol. The costs decrease further with the increase of anesthesia duration and reduction of gas flow rate.